Novo Nordisk | NVO - Operating Profit


Novo Nordisk reported DKK5.25B in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
ANI Pharmaceuticals USD 39.84M 1.13M Jun/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
Bausch Health Companies USD 776M 287M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Canopy Growth CAD -27.47M 14.81M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Drreddys Laboratories INR 829M 13.5B Mar/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Merck USD 840M 2.72B Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Novo Nordisk DKK 5.25B 54.37B Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 23.5M 10.1M Jun/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Zoetis USD 1.12B 256M Jun/2026